Drug Profile
Simlukafusp alfa - Roche
Alternative Names: aFAP-IL2v; FAP-IL2v; FAP-IL2v FP; RG 7461; RO 6874281Latest Information Update: 02 Mar 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Roche
- Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Fibroblast activation protein antagonists; Immunostimulants; Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diffuse large B cell lymphoma; Malignant melanoma; Renal cell carcinoma; Solid tumours
Most Recent Events
- 21 Feb 2023 Hoffmann-La Roche terminates a phase II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in US, France, Germany, Israel, Russia, Switzerland, Turkey, Belgium, New Zealand, Poland, Singapore, South Korea, Spain, Taiwan, and the United Kingdom (NCT03386721) (EudraCT2017-003182-94)
- 10 Nov 2022 Roche completes a phase I trial in in Solid tumors (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Denmark, France, Italy, Netherlands, Spain, United Kingdom, USA (IV) (NCT02627274)
- 14 Jul 2022 Roche completes a phase I trial in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia, Belgium, Canada, France, Russia, Spain and USA (IV) (NCT03875079)